ANTHEMAnthem Biosciences Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · ICRA: AA (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.9 this quarter.
Momentum from moving averages, Supertrend and RSI.
1 forensic issue found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
1 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹594 Cr | ₹211 Cr | 40.53% | 35.60% | ₹3.75 | 90.5x |
| Q1 FY2027 | ₹418 Cr | ₹120 Cr | 28.83% | 28.68% | ₹2.13 | 165.3x |
| Q4 FY2026 | ₹611 Cr | ₹190 Cr | 37.26% | 31.06% | ₹3.38 | 147.3x |
| Q3 FY2026 | ₹423 Cr | ₹93 Cr | 28.99% | 21.93% | ₹1.65 | Negligible |
| Q2 FY2026 | ₹550 Cr | ₹173 Cr | 33.53% | 31.53% | ₹3.09 | 76.8x |
| Q1 FY2026 | ₹540 Cr | ₹136 Cr | 30.55% | 25.14% | ₹2.43 | 116.7x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.